Patents by Inventor George D. Hartman

George D. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Publication number: 20040220201
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 4, 2004
    Inventors: Mark T. Bilodeau, Peter J. Manley, Adrienne Balitza, George D. Hartman, Leonard Rodman
  • Tyrosine kinase inhibitors
    Publication number: 20040192926
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 11, 2004
    Publication date: September 30, 2004
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma Jr
  • Tyrosine kinase inhibitors
    Publication number: 20040192725
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 24, 2004
    Publication date: September 30, 2004
    Inventors: Yuntae Kim, Barbara Hanney, Keith L. Spencer, George D. Hartman, Kenneth L. Arrington
  • Tyrosine kinase inhibitors
    Patent number: 6794393
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20040181066
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: September 16, 2004
    Inventors: Mark E. Fraley, William F. Hoffman, George D. Hartman
  • Integrin receptor antagonists
    Patent number: 6784190
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: August 31, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • Benzazepinone alpha vintegrin receptor antagonists
    Publication number: 20040142919
    Abstract: The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 22, 2004
    Inventors: Robert S. Meissner, Paul J. Coleman, Mark E. Duggan, George D. Hartman, Jiabing Wang, John H. Hutchinson
  • Combination therapy
    Publication number: 20040102360
    Abstract: The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.
    Type: Application
    Filed: October 3, 2003
    Publication date: May 27, 2004
    Inventors: Stanley F. Barnett, Deborah D. DeFeo-Jones, George D. Hartman, Hans E. Huber, Steven M. Stirdivant, David C. Heimbrook
  • Tyrosine kinase inhibitors
    Publication number: 20040063720
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Methods and compositions for treating peridontal disease
    Publication number: 20040053968
    Abstract: The present invention provides for a method for the treatment of alveolar bone loss due to periodontal disease in a subject in need of such treatment comprising administration of a therapeutically effective amount of an &agr;v&bgr;3 integrin receptor antagonist in combination with a therapeutically effective amount of a COX-2 inhibitor. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating the alveolar bone loss due to periodontal disease.
    Type: Application
    Filed: July 1, 2003
    Publication date: March 18, 2004
    Inventors: George D. Hartman, Sevgi B.. Rodan, Gideon A. Rodan
  • Tyrosine kinase inhibitors
    Patent number: 6586423
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 6586424
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Tyrosine kinase inhibitors
    Publication number: 20030100567
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 19, 2002
    Publication date: May 29, 2003
    Inventors: Mark T. Bilodeau, George D. Hartman
  • Tyrosine kinase inhibitors
    Publication number: 20030064996
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 1, 2002
    Publication date: April 3, 2003
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Tyrosine kinase inhibitors
    Publication number: 20020147203
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 1, 2002
    Publication date: October 10, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Tyrosine kinase inhibitors
    Publication number: 20020137755
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 6420382
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: July 16, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hungate
  • &agr;v integrin receptor antagonists
    Patent number: 6410526
    Abstract: The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: June 25, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, Robert S. Meissner, James J. Perkins
  • Inhibitors of prenyl-protein transferase
    Patent number: 6376496
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
  • Inhibitors of prenyl-protein transferase
    Patent number: 6358956
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including-farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Gerald E. Stokker